Study Title: Accelerated Diagnosis of neuro Endocrine and Pancreatic TumourS
Short Title: ADEPTS Study (formally referred to as TRANSBIL)
Pancreatic cancer is difficult to diagnose as many people have vague symptoms or no symptoms at all. It is mostly diagnosed at a late stage when it has already spread and can therefore lead to poor outcomes for patients. Just one per cent of those diagnosed will live for ten years or more after diagnosis.
Currently the best non-invasive tests for pancreatic cancer are MRI and CT scans, but they cannot accurately detect early cancer or reliably tell the difference between cancer and pre-cancerous growths. By developing a urine and blood test, it is hoped that pancreatic cancer can be detected at an earlier stage to allow successful treatment.
ADEPTS Study (formally referred to as TRANSBIL: TRANSlational research in BILiary tract and pancreatic diseases) is an early biomarker study which aims to detect pancreatic cancer in patients at a much earlier stage.
Previous studies have identified biomarker molecules in blood and urine. This study aims to develop a prospective biobank and an early diagnostic tool that can differentiate early PDAC (pancreatic ductal adenocarcinoma), PNETs (pancreatic neuroendocrine tumours) and high-risk pancreatic lesions from benign disease, by combining a risk factor / early symptom electronic clinical decision support tool (e-CDST) with novel panels of blood and urine biomarkers of early disease. This diagnostic tool may then be used for surveillance of high risk populations and triage of patients with non-specific symptoms concerning for pancreatic cancer. The ADEPTS study will recruit 2500 subjects.
Sponsor: University College London
Funder: Pancreatic Cancer UK